Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903552 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
NCT00903552 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 221 participants.
The verdict
NCT00903552, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
Study Summary
This is a phase 2A randomized, double blind, placebo controlled trial to evaluate the safety and immunogenicity of a trivalent seasonal influenza virus-like particle (VLP) vaccine (recombinant) in healthy adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Influenza VLP Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903552
The ClinicalTrials.gov registry entry for NCT00903552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00903552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00903552 about?
NCT00903552 is a clinical study titled "Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)". This is a phase 2A randomized, double blind, placebo controlled trial to evaluate the safety and immunogenicity of a trivalent seasonal influenza virus-like particle (VLP) vaccine (recombinant) in healthy adults.
What is the current status of trial NCT00903552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2009-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00903552?
The interventions under investigation include: Placebo (BIOLOGICAL), Influenza VLP Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00903552?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.